Cite

HARVARD Citation

    Stranzenbach, R. et al. (2018). Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T‐cell lymphoma: reply from the authors. British journal of dermatology. p. 303. [Online]. 
  
Back to record